AbsTrACT background/Aims To determine the UK incidence, demographics, aetiology, management and visual outcome for children developing choroidal neovascularisation (CNV). Methods A prospective population-based observational study of routine practice via the British Ophthalmological Surveillance Unit between January 2012 and December 2013 with subsequent 1-year follow-up in children under 16 years old with newly diagnosed CNV. results Twenty-seven children with CNV were reported. The UK estimated annual incidence for those aged 16 and under was 0.21 per 100 000 (95% CI 0.133 to 0.299). The mean age was 11.1 years (SD 3.9, range 4-16). Fourteen were female. Seventy-seven per cent (22 patients) were Caucasian British. Twenty-three children (85%) had unilateral disease. The most common aetiology included inflammatory retinochoroidopathy (n=9), optic disc abnormalities (n=9) and idiopathic (n=5). Optical coherence tomography was performed in all cases and fundus fluorescein angiography in 61%. Management included observation only (n=10), anti-vascular endothelial growth factor (anti-VEGF) injection of bevacizumab (n=14) or ranibizumab (n=2), or both (n=1), and additional use of oral (n=1) and local (periocular n=2 and intravitreal n=2) steroids in five children with inflammatory retinochoroidopathy. The mean number of anti-VEGF injections was 2±1, with eight patients receiving only one injection. The mean (SD) best corrected visual acuity in LogMAR was 0.91 (0.53) at presentation and 0.74 (0.53) at 1-year follow-up (p=0.09). Conclusion This is the first population-based prospective study of CNV in children. This is a rare disorder with a poor visual prognosis irrespective of CNV location and the use of anti-VEGF therapy.
InTroduCTIon
In the paediatric population, choroidal neovascularisation (CNV) has been reported in association with infection, inflammation, optic disc anomalies, retinal dystrophies and trauma, and may also be idiopathic. 1 Although causes of CNV have been reviewed before, 1 2 the incidence of CNV in children is unknown; there have been no reported prospective epidemiological studies. The management of CNV in the paediatric setting is challenging, and there are a number of options, such as observation, photodynamic therapy (PDT), laser photocoagulation, submacular surgery and anti-vascular endothelial growth factor (anti-VEGF) agents, all yielding variable visual outcomes. [3] [4] [5] [6] The use of anti-VEGF agents remains controversial as suppressing the physiological role of VEGF may have deleterious effects in children. 3 This British Ophthalmological Surveillance Unit (BOSU) study is the first prospective epidemiological study providing national data on the incidence, aetiology, treatment and visual outcome of CNV in a paediatric population.
MeThods
This was a prospective population-based study performed in association with the BOSU monthly reporting system. 7 8 All ophthalmologists with clinical autonomy (consultant and associate specialist grade; although, we did not ascertain their subspecialty) in the UK receive a monthly reporting card with definitions of the conditions currently under surveillance, and they indicate how many new cases are seen each month. For the 24-month study period between January 2012 and December 2013, ophthalmologists were asked to report any case of new CNV in patients ≤16 years old. Every ophthalmologist who notified a patient to BOSU was sent an initial questionnaire requesting information regarding demographics, aetiology, presenting features and first-line management. A 1-year follow-up questionnaire was also sent to ascertain subsequent management and visual outcome. Ophthalmologists who did not return a questionnaire were sent a reminder letter. Incident and follow-up questionnaires are available as online supplementary files 1 and 2. The protocol of this study adhered to the provisions of the Declaration of Helsinki and was approved by the local ethics committee of Moorfields Eye Hospital and BOSU.
statistical analyses
All statistical analyses were performed using the Statistical Package for the Social Sciences (V.21.0). Continuous variables (best corrected visual acuity [BCVA] baseline, BCVA follow-up and age) are presented as mean (SD) after assessing for normality by inspection of histograms. Categorical variables were compared using Χ 2 test. Differences between BCVA baseline and BCVA follow-up were compared using the paired t-test. For comparison of BCVA at baseline and follow-up among the different CNV locations and management groups, analysis of variance (ANOVA) was used. A p value <0.05 was considered statistically significant. Details of all affected eyes (n=31) are reported in table 1; however, information of only 27 eyes was used for statistical analysis. Bilateral cases were not simultaneous and, in the statistical analysis, we included only the eye that was treated or the most recently diagnosed. In addition, only 16 unaffected eyes were reported on by the respondents. As this is a rare condition, numbers are small, and so the power of this study to detect associations was limited. resulTs reports to bosu leading to estimates of the uK incidence of CnV During the study period, the BOSU used a reporting base of 1245 ophthalmologists. Between January 2012 and December 2013 inclusive, BOSU received 39 reports of patients with CNV (card return rate 75%), of these only 32 incident questionnaires were returned; one patient was older than 16, and was thus excluded; and there were three duplicates and one triplicate (this constituted the same patient referred to other ophthalmologists within the UK for further management, hence the patient was over-reported), each one was only counted once to ensure accurate incidence calculations but with full collection of management data. This left 27 children with the accurately reported target disorder. After 12 months, 96.2% of reporting ophthalmologists returned the 1-year follow-up questionnaire, providing follow-up data on 26 out of 27 cases. The midyear population for 2013 was estimated to be approximately 64.1 million, with a denominator of 12.8 million for children aged 16 and under (the UK Statistic Authority website: http://www. statistics. gov. uk/). The UK estimated annual incidence for those aged 16 and under was 0.21 per 100 000 (95% CI 0.133 to 0.299).
Patient characteristics and presenting details
Based on the 27 patients initially reported, the mean age at presentation was 11.1 years (SD 3.9, range 4-16). Fourteen were female. Seventy-seven per cent (22 patients) were Caucasian British, 2 Caucasian non-British, 1 Indian, 1 African and 1 mixed Caucasian and Black Caribbean. The main sources of referral are reported in figure 1A . Five patients (19%) were asymptomatic at diagnosis, identified through regular hospital surveillance of their pre-existing ophthalmic condition (n=3) and routine vision check with optometrists (n=2). The median duration of symptoms (reduced vision, positive scotoma) was 31 days (range 1-252). The clinical findings are summarised in table 1.
Unilateral presentation was the most common, found in 23 children (85%). Four patients had bilateral presentation: two patients with inflammatory retinochoroidopathy, one with Best disease macular dystrophy and one with bilateral chorioretinal coloboma. In patients with bilateral disease, the localisation of the CNV was the same in both eyes. Nearly half (48%) of cases (n=13) had a subfoveal CNV, seven patients (26%) had peripapillary CNV, and in the remaining 7 (26%) it extended from the peripapillary region to the macula.
The most common aetiology included inflammatory retinochoroidopathy (n=9), of which five cases were secondary to multifocal choroiditis, optic disc abnormalities (n=9), of which five cases were secondary to optic disc drusen, Best disease (n=2), high myopia (n=1), idiopathic (n=5) and one associated with laser toy injury (figure 1B). Twenty-two patients did not have any systemic diseases; however, four patients had a medical history of epilepsy, vitiligo, ventricular septal defect or sarcoidosis. All patients had an optical coherence tomography, and fundus fluorescein angiography was performed in 16 patients (61%) and three cases had indocyanine green angiography (8%). Ultrasound, electrodiagnostic testing and autofluorescence were performed together in one case.
Management included observation only (n=10), anti-VEGF intravitreal injection of bevacizumab (n=14) or ranibizumab (n=2), and both in one case. Eight patients received only one injection, four patients two injections, two patients three injections and two patients (one with optic disc drusen and the other with toxocara uveitis) had four injections. Additional steroid treatment was reported in five patients with inflammation: two patients received a biodegradable intravitreal implant of 700 µg of preservative-free dexamethasone (Ozurdex; Allergan, Irvine, California, USA), two patients had periocular triamcinolone acetonide (4 mg) injection and one patient was treated with oral prednisolone.
A total of 21 patients did not have any complications following treatment. There were no complications among those who received anti-VEGF injections. Two patients with inflammatory CNV treated with anti-VEGF and steroid intravitreal implant reported raised intraocular pressure (patient 16 and patient 27) and cataract formation (patient 16). For three cases, this information was missing and one respondent failed to send back the 1-year follow-up questionnaire.
The mean (SD) spherical equivalent refraction at presentation in the affected eye was 0.30 (2.55) (range −9.25 to 5.00). The presenting mean (SD) BCVA in LogMAR of affected eyes was 0.91 (0.53) and at 1 year was 0.74 (0.53); there was a mild improvement in overall vision compared with the presenting BCVA, although not significant (p=0.09). The distribution of BCVA from baseline to the end of follow-up was similar across the different locations of CNV (ANOVA p=0.46 and p=0.09, respectively). In the macula-only group, BCVA baseline in LogMAR was 0.98 (0.61) and at 1-year follow-up was 0.72 (0.61) (p=0.14); in the peripapillary extending to the macula region, BCVA baseline was 0.85 (0.42) and at 1-year follow-up was 0.64 (0.37) (p=0.12); and in the peripapillary area only BCVA baseline was 0.99 (0.38) and at 1-year follow-up was 1.0 (0.42) LogMAR (p=0.77; figure 1C) . Overall, during the follow-up, 5 patients (19%) maintained the same BCVA, 15 (58%) reported a slight improvement and 6 patients (23%) a reduction. One patient did not have visual acuity follow-up. There was no statistically significant difference in the BCVA at the end of follow-up between the different management groups (ANOVA=0. 
dIsCussIon
This is the first population-based prospective study of CNV in children. The disorder is rare with an annual incidence in the UK for those aged 16 and under of 0.21 per 100 000. Two retrospective studies of CNV in children younger than 18 years 2 9 reported opposing gender preponderance, with Barth et al 9 reporting a strong female predominance (80%), in contrast to Rishi et al, 2 who described a higher male preponderance (63%). This result may be due to the different ethnic background and access to healthcare facilities. In our study, no gender preference was identified and the visual acuity outcome was the same in both groups. CNV in the paediatric age group is generally seen in older children, 2 9 although it has been reported in a 4-month-old 10 with congenital toxoplasmosis and a 3-year-old with North Carolina macular dystrophy. 11 In our study, the youngest presentation was seen in two female 4-year-olds with optic disc anomalies, but the majority of cases were in older children with a mean age at presentation of 11 years. The most common aetiologies were inflammatory disease, particularly multifocal choroiditis and optic disc anomalies, which is in concordance with Rishi and colleagues, whereas Barth et al 9 reported choroidal osteoma followed by hereditary macular dystrophy as the most common causes. Both studies reported that most CNVs were subfoveal. There was an equal divide, with half our patients developing subfoveal CNV and the other half having extrafoveal CNV extending from or solely involving the peripapillary region.
Before the advent of anti-VEGF therapy, most cases of CNV in children were managed by observation, but there were a few reports of the outcome of submacular surgery 4 12 or PDT. 6 13 The lack of calcification, thickening of Bruch's membrane and a solitary ingrowth site were better candidates for surgery. 14 The visual outcomes of 35 children with CNV who underwent surgery revealed 90% had a preoperative visual acuity of 0.6 LogMAR or worse and 75% gained two or more Snellen lines in visual acuity postsurgery. 4 5 Mateo and colleagues 12 reported two cases of submacular surgery for CNV in children associated with optic disc drusen: a 16-year-old boy whose visual acuity improved from 1.0 LogMAR to 0.09 LogMAR at 26-month follow-up, and a 12-year-old boy with an improvement from 0.40 to 0.09 LogMAR at 24-month follow-up without any evidence of recurrence. However, a 9-year-old girl with bilateral peripapillary CNV with subfoveal extension in the left eye secondary to optic disc drusen underwent submacular surgery, and her visual acuity worsened from 0.05 to 0.3 in the left eye but did not change from 0.3 in the right eye during the 6-month postoperative period. 15 The results of PDT in paediatric CNV are also encouraging. 6 13 Twelve patients with age range 4−15 years underwent PDT for CNV associated with toxoplasma, Best disease or idiopathic causes. Follow-up ranged from 7 to 77 months, and PDT was able to reduce leakage in 10 out of 12 cases, with an improvement in visual acuity in nine cases. The treatment was safe and effective, but there was an intrinsic risk of the regressed membrane leaving a scar causing a reduction in visual acuity over time.
The most common treatment for CNV in children reported in our survey was intravitreal anti-VEGF injection, and steroids in inflammatory cases. There were no cases of PDT, focal laser and submacular surgery reported. There are no randomised prospective clinical trials that assess the interventions for CNV in childhood, but anti-VEGF treatment seems to have become the Clinical science preferred first-line approach. Several case reports reported in the literature describe the treatment of CNV associated with optic disc drusen with anti-VEGF agents. 16 17 Anti-VEGF agents do not appear to be associated with any ocular toxicity in the developing eye in humans, and this is supported by experimental studies in animals. 18 However, some authors considered treatment with bevacizumab in infants with retinopathy of prematurity (ROP) a significant risk for retinal function and the development of the retinal vasculature. 19 A more serious concern is whether leakage of anti-VEGF agents into the circulation after intravitreal injection may interact with VEGF receptors in other tissues such as the developing brain. A recent observational study found that infants with ROP who were treated with bevacizumab (had a more severe form of ROP) also had a greater risk of neurodevelopmental disabilities, such as motor delay, compared with those who received laser treatment (but had overall less severe disease). 20 There are no clinical studies that are large enough to evaluate the systemic effects of intravitreal anti-VEGF drugs in children. A multicentre retrospective study reported no ocular or systemic side effects relating to anti-VEGF treatment for CNV, Coats disease, familial exudative vitreoretinopathy and cystoid macular oedema at 1-year follow-up 3 in 90 children, in concordance with no reported side effects in our survey. Avery 21 suggested that ranibizumab may be more appropriate for children due to its shorter serum half-life. Regarding the dosage, some studies use a standard adult dose of 1.25 mg/0.05 mL of bevacizumab or 0.5 mg/0.05 mL of ranibizumab 22 as there is little difference in ocular volume between older children and adult eyes; preterm infants with a smaller ocular size require a lower dosage. 23 The number of injections required to control the disease was lower compared with adults, 3 and this was supported by the favourable course of CNV in younger subjects reported by Spaide, 24 attributed to the better health of the retinal pigment epithelium (RPE) pump. 2 In our cohort, steroid use was required in combination with anti-VEGF injections in five children affected by inflammatory retinochoroidopathy. The antiangiogenic approach for inflammatory CNV has already been described and identified to be effective when the inflammation is controlled. 25 Observation remains an important management option. Previous papers report spontaneous regression in 58% 26 and 41.7% 2 of the eyes. A characteristic finding that may be predictive of regression is a pigmented ring or encapsulation around the lesion. 27 In our cohort, among the observation group, 7 out of 10 cases had a spontaneous improvement in visual acuity, although overall the visual outcome remained poor. Subfoveal location of the CNV complex, exudative detachment, subretinal pigment epithelial haemorrhage and cystoid degenerative changes of the neurosensory retina may strongly compromise the visual outcome. 27 Ninety per cent of patients in a case series with initial visual acuity of less than 1.0 LogMAR remained unchanged. 26 In our sample, almost half of the patients did not report any significant subjective changes in visual acuity during the follow-up, but 33% showed a slight objective improvement.
A potential limitation of this study could be the underascertainment of CNV from referring UK ophthalmologists. The high card return rate and previous evaluation of the methodology suggest good levels of compliance, but the incidence of CNV in children in this study is a minimum estimation. The study was not designed to evaluate different methods of treatment and can only give a snapshot of treatment modalities used in current UK practice and the general visual outcomes.
In conclusion, inflammatory retinochoroidopathies and optic disc abnormalities are the most common associations with CNV in the paediatric population. Most affected eyes will have a subfoveal CNV location. However, we found no evidence of a relationship between CNV location and baseline VA. Eyes treated with anti-VEGF with a macula or peripapillary CNV extending to the macula resulted in a slight improvement in VA, but the observation-only group reported a similar VA improvement. Patients with peripapillary CNV did not show any improvement using anti-VEGF or steroids, whereas a slight improvement was found if they were observed. It should be noted, however, that because this is a rare condition, numbers are small and thus the power to detect differences is low. Ocular comorbidities play an important role in deciding the choice of treatment and they have an important impact on the visual outcome. No particular treatment has been validated, but laser coagulation, PDT and submacular surgery are not being employed in the UK for this condition.
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